RecruitingPhase 1NCT06655662

Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.

Studying Thalassemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shenzhen Hemogen
Principal Investigator
Chao Liu, PHD
Shenzhen Hemogen
Intervention
β-globin restored autologous hematopoietic stem cells(other)
Enrollment
8 target
Eligibility
6-35 years · All sexes
Timeline
20242026

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06655662 on ClinicalTrials.gov

Other trials for Thalassemia

Additional recruiting or active studies for the same condition.

See all trials for Thalassemia

← Back to all trials